Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 2 FDA

Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Phase 1 Active not recruiting

67 enrolled

Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Phase 1/2 Completed

23 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02535533 2025-05-20

SLM + Axitinib for Clear Cell RCC

Phase 1 Completed

46 enrolled

Genitourinary

Kidney Neoplasms

Clinical Trials

NEOPAX

SAMURAI

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

SPARCC

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

KEYNOTE-426

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

International Multicentric Study ARON-1

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

PADRES

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

JAVELIN Renal 101

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

SLM + Axitinib for Clear Cell RCC